Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
EXELIXIS INC (EXEL) combines strong fundamentals with a bullish technical setup. Its robust earnings growth, zero debt, and accelerating EPS align with a stock poised for a potential breakout. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Exelixis (EXEL) is a financially strong oncology biotech with high profitability, zero debt, and a low valuation relative to its earnings growth, fitting key value investing principles. 
Via Chartmill
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Preview: Exelixis's Earnings ↗
 
Via Benzinga
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
Exelixis (EXEL) exemplifies GARP investing with strong oncology earnings growth, a debt-free balance sheet, and a valuation discounted versus biotech peers. 
Via Chartmill
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
From Exelixis, Inc.
Via Business Wire
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
These drugmakers are poised to profit from their innovative engines. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
Discover EXELIXIS (EXEL), a value stock with strong profitability, zero debt, and solid growth, trading at an attractive discount to its industry peers. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗
Exelixis (EXEL) is a GARP stock with strong earnings growth, a reasonable valuation, and a debt-free balance sheet. 
Via Chartmill
News headline image
S&P 500 Surges as Congress Nears End to Protracted Government Shutdown
Washington D.C. – November 10, 2025 – Global financial markets are breathing a collective sigh of relief today as the S&P 500 index experiences a significant uplift, signaling investor optimism over... 
Via MarketMinute
Topics Economy Regulatory Compliance Stocks
News headline image
Global Markets Rally on Hopes for US Government Shutdown Resolution
Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
What's Driving the Market Sentiment Around Exelixis Inc? ↗
 
Via Benzinga
News headline image
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗
Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector. 
Via Chartmill
News headline image
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Exelixis, Inc.
Via Business Wire
News headline image
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
From Exelixis, Inc.
Via Business Wire
News headline image
The Ultimate Biotech Stock to Buy With $50 Right Now ↗
This innovative drugmaker still has plenty of upside potential. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗
Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗
Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.